RT Journal Article SR Electronic T1 Efficacy and Safety of Weekly Paclitaxel in Breast Cancer With Symptomatic Bone Marrow Infiltration JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 2955 OP 2960 DO 10.21873/anticanres.14274 VO 40 IS 5 A1 ANGELIQUE DA SILVA A1 CHRISTELLE LEVY A1 DJELILA ALLOUACHE A1 IOANA HRAB A1 ADELINE MOREL A1 AUDREY FAVEYRIAL A1 KATHARINA GUNZER A1 ALISON JOHNSON A1 CARINE SEGURA A1 IDLIR LICAJ A1 GANDHI DAMAJ A1 GEORGE EMILE YR 2020 UL http://ar.iiarjournals.org/content/40/5/2955.abstract AB Background/Aim: Currently, there is no recommendation for the treatment of breast cancer (BC) with bone-marrow cell infiltration (BMI). We evaluated the efficacy and safety of weekly-paclitaxel in this population. Patients and Methods: This retrospective study included all BC patients with BMI receiving weekly-paclitaxel between January 2014 and May 2018. Overall-survival (OS) was the primary endpoint. Secondary endpoints were progression-free-survival (PFS) and safety. Results: BMI was diagnosed in 26 patients. This infiltration was suggested by peripheral blood smear in 73% of cases. All patients had anemia, and 77% had thrombocytopenia. OS and PFS were 7.2 months [95% confidence interval (CI)=2.6-20.7] and 3.3 months (95%CI=1.6-7.2), respectively. Good performance-status, absence of thrombocytopenia and presence of less than 5% of circulating erythroblasts at BMI diagnosis, were associated with better survival. One patient presented grade 5 febrile neutropenia but no episodes of bleeding were reported. Conclusion: Weekly-paclitaxel is an effective therapeutic option with limited toxicity for BC with BMI.